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Abstract
Background:  Increasing antimicrobial resistance among the key pathogens responsible for
community-acquired respiratory tract infections has the potential to limit the effectiveness of
antibiotics available to treat these infections. Since there are regional differences in the
susceptibility patterns observed and treatment is frequently empirical, the selection of antibiotic
therapy may be challenging. PROTEKT, a global, longitudinal multicentre surveillance study, tracks
the activity of telithromycin and comparator antibacterial agents against key respiratory tract
pathogens.
Methods: In this analysis, we examine the prevalence of antibacterial resistance in 1,336 bacterial
pathogens, isolated from adult and paediatric patients clinically diagnosed with acute bacterial
sinusitis (ABS).
Results and discussion: In total, 58.0%, 66.1%, and 55.8% of S. pneumoniae isolates were
susceptible to penicillin, cefuroxime, and clarithromycin respectively. Combined macrolide
resistance and reduced susceptibility to penicillin was present in 200/640 (31.3 %) of S. pneumoniae
isolates (128 isolates were resistant to penicillin [MIC >= 2 mg/L], 72 intermediate [MIC 0.12–1
mg/L]) while 99.5% and 95.5% of isolates were susceptible to telithromycin and amoxicillin-
clavulanate, respectively. In total, 88.2%, 87.5%, 99.4%, 100%, and 100% of H. influenzae isolates
were susceptible to ampicillin, clarithromycin, cefuroxime, telithromycin, and amoxicillin-
clavulanate, respectively. In vitro, telithromycin demonstrated the highest activity against M.
catarrhalis (MIC50 = 0.06 mg/L, MIC90 = 0.12 mg/L).
Conclusion: The high in vitro activity of against pathogens commonly isolated in ABS, together with
a once daily dosing regimen and clinical efficacy with 5-day course of therapy, suggest that
telithromycin may play a role in the empiric treatment of ABS.
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Introduction
The incidences of both the acute and chronic forms of
sinusitis have been increasing, and between 10 and 15%
of the population of central Europe are affected annually
[1]. There are an estimated 30 million cases of ABS in the
USA each year [2-4]. Acute sinusitis accounts for 0.5–2.0%
of all upper respiratory tract infections in adults and
between 5–10% in children and therefore is a common
reason for visits to primary care physicians [5]. Although
usually mild in severity, complications can be life threat-
ening, including meningitis, brain abscess, orbital celluli-
tis and abscess, subempyema, osteomyelitis, and nasal
polyposis [6-9].
S. pneumoniae is the most common pathogenic bacterium
responsible for ABS, isolated in 30–50% of cases, fol-
lowed by H. influenzae, isolated in 20–40% of cases.
Moraxella catarrhalis is isolated in 5–10% of cases, beta
haemolytic streptococci in less than 5%, and Staphylococ-
cus aureus in less than 10% although it is often found co-
infecting with other bacteria [10].
Treatment options for ABS are controversial as up to 40%
of patients recover spontaneously, however, studies have
shown that treatment with an antibacterial reduces the
time to recovery from sinusitis, improves symptoms, and
helps to prevent complications [11,12]. Guidelines on
antibacterial use for ABS vary, possibly because of differ-
ent regulations, antibacterial resistance patterns, and eti-
ology in different countries, however, the choice of first-
line antibacterial is similar across treatment guidelines
[3,13-17]. Nearly all recommend amoxicillin, as it is
active against the major causative pathogens of AMS and
is generally well tolerated. For patients with penicillin
allergy, the recommended first-line agents vary in differ-
ent countries. Trimethoprim or trimethoprim-sulfameth-
oxazole is commonly recommended [3,14]. In addition,
the French guidelines have recently been reviewed and tel-
ithromycin has been included as an alternative first-line
agent [15]. Macrolides are not included in the French
guidelines due to the high macrolide resistance prevalence
in France [15,18].
Second line, or alternative antibacterial agents of choice,
are clarithromycin or second-generation cephalosporins
such as cefuroxime and cefpodoxime, third-generation
cephalosporins such as cefdinir, and trimethoprim-sul-
phamethoxazole [3,5,16,17]. Telithromycin has been rec-
ommended as an alternative agent in Germany [13,16].
High-dose amoxicillin-clavulanate should be used if the
patient does not improve [3,16,17]. In France, anti-pneu-
mococcal fluoroquinolones are recommended after bacte-
rial confirmation or if the patient is at high risk of
complications [15]. A single dose of ceftriaxone can be
used in a child who cannot be treated orally, i.e. vomiting
[17].
However, due to increasing levels of resistance in bacterial
respiratory tract pathogens to these commonly used anti-
bacterials (particularly the rapid emergence of penicillin-
and macrolide-resistant strains of pneumococci), new
agents are required that have high in vitro activity and
demonstrated clinical efficacy against bacterial pathogens
causing community-acquired respiratory tract infections
(RTI's) [19-22]. Telithromycin is the first ketolide
approved for clinical use. The ketolides are semisynthetic
derivatives of the 14-membered ring macrolide erythro-
mycin and have high in vitro activity against the common
community-acquired RTI pathogens [23]. Clinical trials
have demonstrated the efficacy and tolerability of telithro-
mycin therapy in ABS [24-26].
The PROTEKT (Prospective Resistant Organism Tracking
and Epidemiology for the Ketolide Telithromycin) study
is a longitudinal, global multicentre surveillance study
designed in part to determine the activity of telithromycin
against community-acquired RTI isolates, in relation to
the frequency of prescribing, in the regions where the
study is conducted [27]. The aim of this paper is to focus
on the data gathered in the PROTEKT surveillance study to
determine the in vitro efficacy of the new ketolide telithro-
mycin and comparator agents against bacterial pathogens
isolated from the subset of patients with clinically diag-
nosed ABS collected in PROTEKT (2000–2001, and
2001–2002).
Materials and Methods
Patients and bacterial isolates
Detailed study design, including patient selection and
methodology for isolate identification and storage in the
PROTEKT study has been described previously [27]. The
isolates in this sub-study of PROTEKT were selected from
those patients presenting with clinically diagnosed ABS in
which the isolates were determined clinically to be the
pathogenic organism and the specimen type was sinus
aspirate or nasopharyngeal swab/aspirate only. Method-
ology for sinus aspiration was that used routinely by the
investigator.
Antimicrobial testing
MIC susceptibility status was determined, using the
National Committee of Clinical and Laboratory Standards
(NCCLS) breakpoints, at a central laboratory (GR Micro
Ltd, London, UK) from a panel of existing and new anti-
bacterials, using the NCCLS broth microdilution method
and lyophilised microtitre plates (Sensititre, Trek Diag-
nostics) [28]. NCCLS breakpoints were used for interpre-
tation of MIC's [29]. Tentative NCCLS breakpoints for
telithromycin are: S. pneumoniae and S. aureus, ≤ 1 µg/mlAnnals of Clinical Microbiology and Antimicrobials 2004, 3:15 http://www.ann-clinmicrob.com/content/3/1/15
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is susceptible, 2 µg/ml is intermediate, and ≥ 4 µg/ml is
resistant; for Haemophilus influenzae, ≤ 4 µg/ml is suscepti-
ble, 8 µg/ml is intermediate, and ≥ 16 µg/ml is resistant
[29].
Statistical analysis
Statistical analysis was performed using a χ2 test.
Results
A total of 1,336 bacterial pathogens in all were collected
from 25 countries within Western Europe (n  = 652),
North America (n = 14), Latin America (n = 207), Asia (n
= 464), Eastern Europe (n = 68), Australia (n = 2), and
South Africa (n = 126) in the PROTEKT study from years
2000–2001 and 2001–2002 for analysis of the suscepti-
bility of bacterial pathogens isolated from patients with
acute sinusitis. Gender distribution was 52.2% male (695
patients), 46.7% female (624 patients); gender was not
provided for 1.3% of patients. Almost two thirds (66.3%)
of patients were in the 0–12 year age group, one third
(29.7%) in the 13–65 year age group, 2.7% in the over 65
year age group and age was not specified in 1.3% of
patients. S. pneumoniae was the pathogen most frequently
isolated (47.9% of isolates) followed by H. influenzae
(24.6% of isolates) (Table 1).
MIC data for isolates from patients with ABS demon-
strated that the in vitro activity of telithromycin against
gram-positive cocci was similar to amoxicillin-clavulanate
and was higher and more potent than clarithromycin and
beta-lactams tested such as cefuroxime (Table 2). In total,
99.5 % of streptococcal isolates were susceptible to tel-
ithromycin. With the exception of S. aureus isolates more
than 90% of gram-positive cocci were inhibited at a tel-
ithromycin MIC of 0.25 mg/L (Table 2).
Resistance to most antibiotics was slightly greater in
nasopharyngeal specimens than sinus aspirates (Table 2).
Considerable variation in in vitro antibiotic activity was
apparent between geographical regions as observed in the
key examples shown in Table 3. Insufficient data were
available for analysis by country.
Combined macrolide resistance and reduced susceptibil-
ity to penicillin was present in 200/640 (31.3 %) of S.
pneumoniae isolates (128 isolates were resistant to penicil-
lin [MIC >= 2 mg/L], 72 intermediate [MIC 0.12–1 mg/
L]). Of note, 3 isolates of S. pneumoniae were non-suscep-
tible to telithromycin (2 isolates intermediate with an
MIC of 2 mg/L, 1 isolate resistant with an MIC of 8 mg/L).
This represented 0.5% of isolates, a value that is signifi-
cantly (p < 0.001) lower than those obtained by erythro-
mycin (44.1%), clarithromycin (44.2%) and cefuroxime
(33.9%).
Of the 329 H. influenzae isolates, 34 (10.3 %) were posi-
tive for β-lactamase production. All isolates of H. influen-
zae  were susceptible to amoxycillin-clavulanate and
telithromycin with an MIC90 of 1 and 2 mg/L, respectively.
Amoxycillin-clavulanate and telithromycin were more
potent and had greater activity than clarithromycin
(MIC90 = 16 mg/L, 87.5% susceptible). This activity was
comparable to azithromycin (MIC90  = 2 mg/l, 100%
susceptible).
Although the number of S. aureus isolated from the total
number of specimens was small (116/1366 isolates), tel-
ithromycin was as efficacious as comparators. Of the 116
isolates, 11 were resistant to methicillin (MRSA) and 105
were methicillin susceptible (MSSA). Ninety-nine
(94.3%) of the MSSA isolates and 5 of the 11 MRSA iso-
lates were susceptible to telithromycin. Of note, all of the
S. pyogenes isolates were inhibited by ≤ 1 mg/L telithromy-
cin, despite 17.7% resistance to erythromycin and
clarithromycin.
Telithromycin was the most potent antimicrobial against
M. catarrhalis with an MIC50 of 0.06 mg/L and MIC90 of
0.12 mg/L. β-lactamase production was detected in 97.6%
of these isolates.
Discussion
The data in this analysis demonstrates that telithromycin
has high in vitro activity against bacterial pathogens iso-
lated from a large, globally distributed population of
Table 1: Distribution of species by specimen type for the 1336 bacterial pathogens causing acute sinusitis [n (%)]
Specimen S. pneumoniae H. influenzae M. catarrhalis S. aureus S. pyogenes Total
Sinus 272 (47.5) 148 (25.9) 67 (11.7) 64 (11.2) 21 (3.7) 572 (42.8)
Nasopharynx1 368 (48.1) 181 (23.7) 145 (19.0) 52 (6.8) 18 (2.4) 764 (57.2)
Total 640 (47.9) 329 (24.6) 212 (15.9) 116 (8.7) 39 (2.9) 1336 (100)
1Aspirate or swabAnnals of Clinical Microbiology and Antimicrobials 2004, 3:15 http://www.ann-clinmicrob.com/content/3/1/15
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patients diagnosed with ABS. Telithromycin was the most
active and potent agent against all isolates of the patho-
gens isolated from patients with ABS with 99.4% of iso-
lates susceptible. Not surprisingly, high levels of penicillin
resistance, macrolide resistance, and combined penicillin
and macrolides resistance were prevalent in S. pneumoniae
Table 2: In vitro activity of antibacterial agents and percent susceptible against 1336 bacterial pathogens isolated from patients with 
clinically diagnosed acute sinusitis
Organism N (total, SA1, NP2) Antibiotic MIC (mg/L) Percent 
susceptible 
(Total, SA, NP)
Range 50 90
S. pneumoniae 640, 272, 368 Penicillin 0.008 – 8 0.06 2 58.0, 64.7, 53.0
Amoxicillin-clavulanate 0.015 – 8 0.03 2 95.5, 95.2, 95.7
Cefuroxime 0.015 – 16 0.12 8 66.1, 73.2, 60.9
Cefpodoxime 0.12 – 32 0.12 2 65.0, 71.7, 60.1
Trimethoprim-sulphamethoxazole 0.12 – 32 0.5 8 56.3, 58.1, 54.9
Erythromycin 0.03 - >64 0.06 >64 55.9, 60.7, 52.5
Clarithromycin 0.015 - >32 0.06 >32 55.8, 60.7, 52.2
Azithromycin 0.03 - >64 0.12 >64 55.8, 60.7, 52.2
Telithromycin 0.008 – 8 0.015 0.12 99.5, 98.9, 100
H. influenzae 329, 148, 181 Ampicillin 0.12 – 32 0.25 8 88.2, 91.2, 85.6
Amoxicillin-clavulanate 0.12 – 4 0.5 1 100, 100,100
Cefuroxime 0.12 – 16 1 2 99.4, 99.3, 99.5
Cefpodoxime 0.015 – 4 0.06 0.25 99.4, 100, 98.9
Cefdinir 0.06 – 4 0.25 0.5 97.3, 96.0, 98.3
Trimethoprim-sulphamethoxazole 0.03 – 16 0.06 4 84.5, 82.4, 86.2
Erythromycin 0.25 – 16 4 8 -3
Clarithromycin 0.25 – 32 8 16 87.5, 87.2, 87.9
Azithromycin 0.06 – 4 1 2 100, 100,100
Telithromycin 0.06 – 4 1 2 100, 100,100
M. catarrhalis 212, 67, 145 Ampicillin 0.12 – 32 4 16 -
Amoxicillin-clavulanate 0.12 – 0.5 0.12 0.25 -
Cefuroxime 0.12 – 16 1 4 -
Cefpodoxime 0.06 – 4 0.5 1 -
Cefdinir 0.06 – 1 0.12 0.25 -
Trimethoprim-sulphamethoxazole 0.03 – 2 0.12 0.25 -
Erythromycin 0.25 – 1 0.25 0.25 -
Clarithromycin 0.25 – 0.5 0.25 0.25 -
Azithromycin 0.06 – 0.25 0.06 0.06 -
Telithromycin 0.004 – 0.5 0.06 0.12 -
S. aureus 116, 64, 52 Methicillin - - - 90.5, 92.2, 88.5
Amoxicillin-clavulanate 0.06 – 8 0.5 4 90.5, 92.2, 88.5
Cefuroxime 0.5 – 16 1 2 90.5, 92.2, 88.5
Cefpodoxime 1 – 32 2 4 88.8, 92.2, 84.6
Trimethoprim-sulphamethoxazole 0.12 – 32 0.12 0.12 96.6, 95.3, 98.1
Erythromycin 0.03 - >64 0.25 >64 69.0, 73.4, 63.5
Clarithromycin 0.015 - >32 0.25 >32 69.8, 75.0, 63.5
Azithromycin 0.03 - >64 0.5 >64 69.0, 75.0, 61.5
Telithromycin 0.015 - >32 0.06 2 89.7, 89.1, 90.4
S. pyogenes 39, 21, 18 Penicillin 0.008 – 0.008 0.008 0.008 100, 100,100
Amoxicillin-clavulanate 0.008 – 0.03 0.015 0.015 100, 100,100
Cefuroxime 0.015 – 0.015 0.015 0.015 100, 100,100
Cefpodoxime 0.12 – 0.12 0.12 0.12 100, 100,100
Trimethoprim-sulphamethoxazole 0.12 – 0.5 0.12 0.25 -
Erythromycin 0.03 – 4 0.06 0.25 92.3, 100, 83.3
Clarithromycin 0.015 – 2 0.03 0.25 92.3, 100, 83.3
Azithromycin 0.03 – 16 0.12 0.25 92.3, 100, 83.3
Telithromycin 0.008 – 0.12 0.015 0.015 -
1Sinus aspirate 2Nasopharyngeal aspirate or swab 3No NCCLS interpretive guidelines available or pendingAnnals of Clinical Microbiology and Antimicrobials 2004, 3:15 http://www.ann-clinmicrob.com/content/3/1/15
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although prevalence varied widely between geographical
regions.
Amoxicillin has been the treatment of choice in ABS
because of its general effectiveness, safety, tolerability, low
cost and narrow spectrum [17]. The high prevalence of
beta-lactamase in H. influenzae and M. catarrhalis found in
the present study demonstrate compromised in vitro effi-
cacy of amoxicillin against these isolates. Although the
cephalosporins (cefuroxime, cefpodoxime and cefdinir)
showed high activity against H. influenzae (including beta-
lactamase positive strains), resistance to these agents was
high in S. pneumoniae: >30% for cefuroxime and cefpo-
doxime – cefdinir was not tested against pneumococci in
PROTEKT, however susceptibility is usually similar to the
other cephalosporins reported here [30].
Similarly, macrolides are prescribed in various countries
for ABS and an overall resistance rate for S. pneumoniae of
44.1% to erythromycin, azithromycin, and clarithromy-
cin was found. Trimethoprim-sulfamethoxazole activity
was low for S. pneumoniae (56.3% susceptible) and
decreased for H. influenzae (84.5% susceptible).
Respiratory fluoroquinolones are recommended second-
line treatment options in some countries (references
needed to support this statement). However, recent evi-
dence suggests that resistance to fluoroquinolones is rap-
idly developing in pneumococci and other pathogens
(including gram-positive and gram-negative [31-34]. To
preserve the long-term utility of fluoroquinolones,
including their use in the treatment of serious non-respi-
ratory infections, it has been recommended that respira-
tory fluoroquinolones be reserved for treating severe (e.g.
hospitalized) community-acquired RTIs only [35,36].
The high prevalence of beta-lactam, macrolide, TMP-SMX
resistance demonstrated in the large number of isolates
from patients with clinically diagnosed sinusitis in our
study demonstrates the need to be exploring new thera-
peutic options, especially in geographical regions of high
prevalence such as the Far East.
The high in vitro activity of telithromycin against ABS
pathogens reported in this study, regardeless of geograph-
ical region, also demonstrates its potential as an empiric
therapeutic option for ABS. There are several other reasons
to consider this option – 1) High rates of clinical cure and
bacteriological eradication have been demonstrated using
telithromycin against sinus isolates of S. pneumoniae, H.
influenzae, M. catarrhalis and S. aureus [24-26]. 2) Telithro-
mycin has been shown to have a targeted spectrum of
activity against the major bacterial respiratory tract patho-
gens and has less effect on normal bacterial ecology [37-
39]. 3) The pharmacokinetic profile of oral telithromycin
allows it to be prescribed with a dosing regime of 800 mg
once daily for 5 days [40,41]. This contrasts favourably
with its comparators, where a 10 – 14 day course with
administration either 2 or 3 times daily, depending on the
chosen antibacterial, is generally prescribed. Studies have
shown that the once daily dosing regime affords greater
patient treatment compliance, thereby avoiding clinical
failure and the ensuing development of antibacterial
resistance [41-43]. 5) Telithromycin has been shown to
have high penetration levels in paranasal sinuses, and it is
preferentially absorbed by polymorphonuclear neu-
trophils (PMNs) within the azurophil granules allowing
effective delivery to phagocytized intracellular bacteria
[44,45].
Although this study provides valuable information on the
overall antimicrobial profile of bacteria causing ABS care
should be taken when interpreting data related to specific
demographics. A major limitation of this study, inherent
to most surveillance studies, is the requirement for collect-
ing centers to fulfill a specified quota of isolates over a
defined time period (1 year). If, for instance, 1 center
manages to fulfill their quota for S. pneumoniae isolates
from patients with community-acquired pneumonia, they
may then only send H. influenzae from patients with ABS
Table 3: Key example of regional variation in in vitro antibiotic activity
Streptococcus pneumoniae Haemophilus influenzae
REGION1 N Penicillin susceptible Erythromycin susceptible N Beta-lactamase positive
Eastern Europe 40 70.0% 82.5% 13 0.0%
Far East 185 24.9% 15.7% 96 13.5%
Latin America 108 63.0% 73.1% 31 6.5%
South Africa 61 37.7% 59.0% 34 2.9%
Western Europe 246 83.7% 73.6% 153 11.8%
Grand Total 640 58.0% 55.9% 329 10.3%
1Australasia and North America not included due to insufficient dataAnnals of Clinical Microbiology and Antimicrobials 2004, 3:15 http://www.ann-clinmicrob.com/content/3/1/15
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to fulfill their quota for this organism. Thus, the potential
exists to over or under estimate the prevalence of a species
in a particular disease. A further limitation of this study is
it is restricted to the major bacterial pathogens causing
sinusitis and does not therefore assess anaerobic bacteria,
which are also known to be involved in this disease. How-
ever, a recent study of sinus puncture specimens demon-
strated that telithromycin had good in vitro activity against
anaerobes involved in sinusitis [46].
The inclusion of nasopharyngeal specimens is a potential
limitation of this study and the higher rate of resistance
compared to sinus aspirates may indicate some isolates
were nasopharyngeal flora rather than pathogens. How-
ever, the difference in resistance prevalence between
nasopharyngeal specimens and sinus aspirates was not
great for any species/antibiotic combination, and assum-
ing the majority of isolates were the responsible pathogen,
significant bias of resistance patterns is unlikely. The treat-
ment of ABS is complicated by a difficulty in establishing
the causative pathogen(s). Sampling of infected fluid
using sinus puncture is a painful and rare procedure [47].
Nasopharyngeal culture is a painless and reliable method
that can help identify patients that may benefit from anti-
bacterial therapy [48] and hence, could be useful in deter-
mining antibiotic resistance implicated in sinusitis –
particularly  Streptococcus pneumoniae and  Haemophilus
influenzae. Additionally, there are regional differences in
the susceptibility patterns observed and, as therapy is usu-
ally empirical, choosing an effective therapy can be chal-
lenging [18,20,49].
In summary, the data presented here demonstrates that
telithromycin has good in vitro activity against S. pneumo-
niae, H. influenzae, M. catarrhalis and S. aureus respiratory
pathogens commonly isolated in ABS. It is as active as or
more active than antibacterial agents that are currently
used in this clinical setting. The development of resistance
will always be a threat to the usefulness of antibacterial
compounds, however surveillance studies such as PRO-
TEKT allow the rapid detection and characterization of
resistance mechanisms and highlight the need for and
examine the in vitro efficacy of newer antibacterial agents.
Providing careful surveillance for the development of
resistance is maintained telithromycin currently offers a
useful therapeutic option in the treatment of AS.
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